Michael Morneau, VP Finance & CAO at Trius Therapeutics Inc (TSRX), sold 20,000 shares at $7.75 ($155K) on 2013-05-14, disclosed to the SEC on 2013-05-16.
Scheduled sale ($155k) by VP Finance & CAO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| Filing → |